

TWO-STEP INACTIVATION OF BEE VENOM PHOSPHOLIPASE A₂ BY SCALARADIAL*†

MARIANNE S. DE CARVALHO and ROBERT S. JACOBS‡

Department of Biological Sciences and Marine Science Institute, University of California, Santa Barbara, CA 93106, U.S.A.

(Received 11 March 1991; accepted 13 June 1991)

Abstract—Scalaradial (SLD), a marine natural product isolated from the sponge (*Cacospongia* sp., possesses anti-inflammatory properties *in vivo* and *in vitro* (*Pharmacologist* 32: 168, 1990). In this study we characterize its effects against bee venom phospholipase A₂ (PLA₂; EC 3.1.1.4). SLD is a potent inactivator of bee venom PLA₂ with an IC₅₀ value of 0.07 µM. Inactivation of bee venom PLA₂ occurred in a time-dependent, irreversible manner. The rate of inactivation followed first-order reaction kinetics and was dependent on the concentration of SLD. Kinetic analysis suggested a two-step mechanism of inactivation: an initial apparent noncovalent binding ($K_i = 4.5 \times 10^{-5}$ M) followed by covalent modification. The rate of inactivation was reduced markedly in the presence of excess phosphatidylcholine, suggesting that modification of the enzyme occurs at or near the substrate binding site.

During our investigations of novel anti-inflammatory agents from marine invertebrates [1, 2], we observed that scalaradial (SLD§) (5 α ,12 α ,17 α)-12-(acetyloxy)-4,4,8-trimethyl-D-homoandrost-16-ene-17,17 α -dicarboxaldehyde), originally isolated by Cimino *et al.* [3], had a basic ring structure which resembled an adrenalcorticoid except that the "D" ring was a cyclohexene ring instead of a cyclopentane ring. Due to the resemblance of SLD to the steroid molecule and the presence of dialdehyde functional groups, which are believed necessary for the potent activity of the anti-inflammatory marine natural product manoalide [4, 5], we hypothesized that SLD could be an important pharmacophore useful for the investigation of inflammation.

Preliminary experiments showed that SLD has potent anti-inflammatory properties *in vivo* when administered topically or systemically against phorbol 12-myristate 13-acetate (PMA)-induced skin inflammation, whereas it does not inhibit arachidonic acid-induced inflammation [6]. In *in vitro* cellular studies, SLD proved to be a potent inhibitor of

PMA-stimulated release of arachidonic acid in the mouse peritoneal macrophage [6]. Further experiments showed that desacetylscalaradial, a SLD structural analog with similar anti-inflammatory properties, inhibits macrophage phospholipase A₂ (PLA₂; EC 3.1.1.4) activity in cell-free homogenates [6]. SLD, in other experiments not reported here, also inhibited macrophage PLA₂ in cell-free homogenates.||

In the present study, we investigated the molecular mechanism of action of SLD using bee venom PLA₂. As reported here, SLD is a potent, apparent irreversible inactivator of bee venom PLA₂, acting at a site near the substrate binding site. Kinetic studies indicate that SLD inactivation of PLA₂ occurs with the formation of an initial noncovalent, reversible Michaelis-type complex prior to covalent modification of the enzyme.

MATERIALS AND METHODS

Materials

L- α -Dipalmitoyl phosphatidylcholine, N-(2-hydroxyethyl)piperazine-N'-2-ethanesulfonic acid (HEPES), and Triton X-100 were obtained from the Sigma Chemical Co. (St. Louis, MO). Bee venom phospholipase A₂ (2400 units/mg protein) was purchased from Boehringer Mannheim (Indianapolis, IN). L- α -Dipalmitoyl-[2-palmitoyl-9,10-³H (N)] phosphatidylcholine (sp. act. 50 Ci/mmol) and [1-¹⁴C]palmitic acid (sp. act. 8.9 mCi/mmol) were purchased from New England Nuclear (Boston, MA). Silica gel 60 was purchased from Merck (Darmstadt, Germany). BioSafe scintillation fluid was obtained from Research Products (Mount Prospect, IL).

PLA₂ radioassay

Phosphatidylcholine substrate was prepared at 1.36 mM as mixed micelles. Briefly, unlabeled L- α -dipalmitoyl phosphatidylcholine was homogenized in 10 mM HEPES buffer, 1 mM CaCl₂, pH 7.4, at

* This work is the result of research sponsored in part by NOAA, National Sea Grant College Program, Department of Commerce, under Grant NA85AA-D-SG140 and NA89AA-D-SG138, Project No. R/MP-38 and R/MP-47, through the California Sea Grant College, and in part by the California State Resources Agency. The U.S. Government is authorized to reproduce and distribute this article for governmental purposes. Marianne S. de Carvalho is a Sea Grant Trainee.

† A preliminary report of this work was presented in *Pharmacologist* 32: 168, 1990.

‡ Author to whom all correspondence should be addressed. Present address: Department of Biological Sciences, University of California, Santa Barbara, CA 93106.

§ Abbreviations: SLD, scalaradial; PMA, phorbol 12-myristate 13-acetate; PLA₂, phospholipase A₂; HEPES, N-(2-hydroxyethyl)piperazine-N'-2-ethanesulfonic acid; and p-BPB, p-bromophenacyl bromide.

|| Manuscript in preparation.

41° containing 0.15% (w/v) Triton X-100. ^3H -Labeled L- α -dipalmitoyl phosphatidylcholine was added to a separate test tube and organic solvent was removed. Unlabeled substrate solution was added and the solution was sonicated until clear in an ice bath for 30 min (final activity of 0.25 $\mu\text{Ci}/0.5\text{ mL}$ substrate). Bee venom PLA₂, 5 μM determined by the Bradford protein assay [7] using bovine gamma globulin as the protein standard, was prepared in 10 mM HEPES buffer, 1 mM CaCl_2 , pH 7.4, at 41°. SLD was dissolved in methanol. The final methanol concentration in SLD and control tubes was 3% before dilution into substrate. SLD/PLA₂ mixtures were incubated at 41° for variable time periods. Enzyme assays were run under conditions previously described [8]. Five microliters of SLD/PLA₂ mixture was added to 0.5 mL of substrate (final enzyme concentration = 50 nM with substrate). After 15 sec at 41° the reaction was terminated with 2 mL isopropyl alcohol/heptane/0.5 M H_2SO_4 (40:10:1, by vol.) and free palmitic acid was extracted as previously reported [8], with modifications, as follows. An additional 2 mL of heptane and 1 mL of H_2O were added and tubes were vortexed and centrifuged. Then 2 mL of the heptane layer was removed and added to tubes containing 150 mg silica. After vortexing and centrifugation at 800 g for 10 min, 1 mL of heptane was removed and added to 3 mL of BioSafe scintillation fluid and counted in an LKB scintillation counter. Extraction efficiency was determined by co-extraction of ^{14}C -labeled palmitic acid in tubes containing no enzyme.

Dialysis studies

Prior to dialysis, 1 mL of enzyme was preincubated at 41° for 1 hr with methanol or SLD. Then 5 μL was removed and assayed for enzyme activity. The remaining solution was dialyzed against 1 L of HEPES buffer at 4° in SpectraPor mol. wt 10,000 cutoff dialysis tubing for 24 hr with two buffer changes before post-dialysis assay.

Progressive inactivation studies

The rate of inactivation of PLA₂ by SLD was determined as follows. SLD was preincubated with 5 μM enzyme and at various times 5 μL was removed and diluted 100-fold into substrate for assay of enzyme activity. Percent enzyme activity remaining at different times was calculated by dividing enzyme activity in the presence of SLD by control enzyme activity from samples that were incubated with methanol and assayed at identical time points.

Kinetic analysis

In initial experiments it was determined that inactivation of PLA₂ followed first-order kinetics; thus, the analysis used by Kitz and Wilson [9] was applied to analyze the SLD-PLA₂ interaction as follows.

Inactivation rates. The rates of inactivation of PLA₂ by SLD were determined by plotting the percent residual enzyme activity versus time of preincubation on a semilogarithmic plot. At least four data points, each the average of duplicate measurements, were used to determine the pseudo





Fig. 1. Inhibition of PLA₂ by SLD. SLD was preincubated with PLA₂ for 1 hr, pH 7.4, 41°. Enzyme activity was assayed as detailed in Materials and Methods. SLD concentrations shown are the final concentration in assay with 50 nM enzyme. Data are means \pm SE (N = 3) of percent inhibition as compared to controls. Control enzyme activity = 0.205 $\mu\text{mol}/\text{min}$.

first-order rates of inactivation (k'). The slopes and intercepts were calculated using linear regression by least squares.

The relationship between the pseudo first-order rate constant (k') and the concentration of SLD was used to estimate the binding constants, K_i and k_3 , for SLD (I) with the bee venom PLA₂ (E). The following reaction scheme (1) represents the hypothetical reaction model where $K_i = k_2/k_1$ is the inhibitor dissociation constant for formation of an initial reversible complex and k_3 is the rate formation of the irreversibly inactivated enzyme (EI*) from the reversible complex (E - I).



Statistical analysis

Data are presented as means \pm SE. Where standard error bars are not visible, the standard error bar was less than or equal to the size of the symbol.

RESULTS

Inhibition of PLA₂ by scleralal

SLD is a potent inactivator of bee venom PLA₂ (Fig. 1). When SLD was incubated with PLA₂ at 41° for 1 hr prior to assay with substrate, a concentration-dependent inhibition occurred over 3 log units with an apparent IC_{50} of 0.07 μM with 50 nM enzyme. At this enzyme concentration complete inactivation could be achieved at SLD concentrations of 0.25 μM and above. During preincubation there was no visible precipitation of the protein giving no evidence of nonspecific denaturation, cross-linking of protein or formation of insoluble aggregates. Additionally, during preincubation of SLD with PLA₂, lysine or cysteine, there was no visible evidence of chromophore formation typical of observations made during the




Fig. 2. Inhibition by SLD as a function of PLA₂ concentration. SLD was preincubated for 1 hr at pH 7.4, 41° with increasing molar concentrations of PLA₂ before addition of an aliquot to the substrate. Concentrations shown are final concentrations in assay. Key: (□) control enzyme activity, and (■) enzyme activity with 0.1 μM SLD. Data are means ± SE (N = 3). The difference between the slopes was not significant, $P \geq 0.05$ (Student's *t*-test).

investigation of the chemical reactivity of manoalide [10].

Irreversible properties

When 10 μM SLD was preincubated with 5 μM PLA₂ for 1 hr at 41°, the enzyme was inhibited by 67% compared to control samples with no SLD. Following dialysis for 24 hr against a 1000-fold volume of HEPES buffer at 4°, no reversal of inhibition was detected when compared against paired control samples dialyzed simultaneously. Post-dialysis control samples retained 84% of activity as compared to pre-dialysis controls (data not shown).

Further evidence that SLD binding was irreversible is based on analysis of plots of the relationship between the initial velocity versus PLA₂ concentration in the presence and absence of SLD (Fig. 2). As can be seen in Fig. 2, there was a parallel shift in the lines indicating a constant reduction in the amount of available enzyme. This relationship is typically obtained with irreversible inhibitors [8, 11]. On the other hand, with reversible inhibitors the two enzyme activity lines converge at their origin [11].

Kinetics of inactivation

Progressive inactivation of PLA₂. When SLD was preincubated with PLA₂ in the absence of substrate, the loss of PLA₂ activity was progressive with time. The time dependence of PLA₂ inactivation for three concentrations of SLD (10, 25, and 100 μM) with 5 μM PLA₂ is shown in Fig. 3. As can be seen, the rate of inactivation increased as the concentration of SLD was increased. At concentrations of less than 25 μM, as the SLD concentration approached the enzyme concentration the data were not linear through 100% inactivation. To accurately determine the degree of irreversibly modified enzyme at the various time points, the PLA₂/SLD mixtures were diluted extensively (100-fold) to dissociate any reversible complexes. At the concentrations used,




Fig. 3. Progressive inactivation of PLA₂ by SLD. SLD was preincubated with 5 μM PLA₂ at pH 7.4, 41°. Enzyme activity is expressed as percent of control samples. Data are means ± range (N = 2–3) from three experiments. Key: (---) 10 μM SLD, control enzyme activity = 0.112 to 0.148 μmol/min over preincubation time; (---) 25 μM SLD, control enzyme activity = 0.116 to 0.170 μmol/min; and (—) 100 μM SLD, control enzyme activity = 0.08 to 0.121 μmol/min.

there was no Michaelis–Menten type of kinetics apparent at the time of addition as the lines routinely intercepted the y axis at 100% control activity.

Calculation of the pseudo first-order rate constants (k') for inactivation of PLA₂. The inactivation of bee venom PLA₂ by SLD exhibited pseudo first-order kinetics. Inactivation was first order through 20% residual enzyme activity at 10 μM SLD and first order through 100% at concentrations of 25 μM and higher with 5 μM enzyme. From these data the pseudo first-order rate constants for inactivation were calculated from the slopes of the inactivation lines from SLD concentrations of 10–100 μM, or from SLD/PLA₂ ratios of 2 to 20 (Fig. 4A). The correlation coefficients for the inactivation lines were greater than 0.86 for all sets of data. The estimated values of k' were dependent on the concentration of SLD and increased from 0.05 min⁻¹ to 0.19 min⁻¹ with an apparent saturation at an SLD/enzyme ratio of 20 (Fig. 4A).

Estimation of the kinetic constants (k_3 and K_i) for SLD inactivation of PLA₂. The binding properties of SLD can be described from a double-reciprocal plot of the relationship between the pseudo first-order rate constant, k' , and the concentration of SLD; and is analogous to the estimation of the K_m and V_{max} for enzyme–substrate interactions (Fig. 4B). The regression line through the points intercepted the positive y axis suggesting that there were reversible complexes formed between the enzyme (illustrated in the kinetic scheme No. 1 in Materials and Methods) and allowed an estimation of the dissociation constant for this complex. The dissociation constant for reversible binding of SLD to bee venom PLA₂ was calculated from the intercept on the x axis, as $K_i = 1/x$ intercept and was equal to 4.5×10^{-5} M. Estimation of the first-order rate constant for formation of irreversibly inactivated enzyme from the reversible complex (k_3) was made from the $1/y$ intercept. The estimated k_3 was 0.27 min⁻¹ at pH 7.4, 41°.




Fig. 4. (A) Changes in pseudo first-order rate constant as a function of SLD concentration. The pseudo first-order rate constant for each SLD/PLA₂ ratio was derived from the slope of the inactivation lines (e.g. Fig. 3). Data are means \pm SE from two experiments (four replicates). * One experiment (two replicates). (B) Double-reciprocal plot $1/k'$ vs $1/(\text{SLD})$ for determination of the kinetic parameters of SLD inhibition of bee venom PLA₂. Data from panel A are plotted in reciprocal form. Correlation coefficient: $r = 0.99$.

Protection of inactivation by substrate

We tested the ability of phosphatidylcholine to alter the rate of inactivation of PLA₂ by SLD. If SLD is binding at the active site, the presence of substrate during the preincubation period should slow the inactivation rate.

The substrate, dipalmitoyl phosphatidylcholine, was prepared as a sonicated dispersion, and was added to the enzyme-inhibitor preincubation mixture in a 10-fold molar excess over the SLD concentration. As can be seen in Fig. 5, in the presence of substrate the inhibition was still time dependent, but the rate of inactivation by SLD was decreased markedly (4.6 fold), suggesting that SLD was competing with the substrate for a binding site on the enzyme. Preincubation of enzyme alone with this concentration of substrate prior to assay did not alter enzyme specific activity.

DISCUSSION

In this study we investigated the mechanism of inactivation of bee venom PLA₂ by the marine natural product SLD. Our data indicate that SLD irreversibly inactivated PLA₂ through a two-step mechanism. As the concentration of SLD was increased, there was an apparent saturation of the




Fig. 5. Effect of substrate on the rate of inactivation of PLA₂ by SLD. SLD was preincubated with PLA₂ at pH 7.4, 41°, in the presence and absence of a 10-fold molar excess of substrate. Enzyme activity is expressed as percent of control samples. Key: (□) SLD (50 μM), and (■) SLD (50 μM) + phosphatidylcholine (500 μM). Data are means \pm range (N = 2). Control enzyme activity = 0.111 to 0.167 μmol/min.

inactivation rate suggesting that a reversible step, prior to covalent modification, limits the rate of irreversible inactivation. The noncovalent complex was characterized by an apparent dissociation constant of 4.5×10^{-5} M. The irreversible step occurred relatively quickly with a rate constant of 0.27 min^{-1} . These two binding characteristics result in a potent inhibition of bee venom PLA₂.

Noncovalent interactions

The data indicating that SLD formed a noncovalent complex with the enzyme raised the question as to whether SLD had an affinity for the active site. When SLD was incubated with the enzyme along with a 10-fold molar excess of substrate the inactivation rate was reduced markedly, suggesting that the substrate may be competing with SLD for a site on the enzyme though the possibility of a hydrophobic interaction between SLD and the phosphatidylcholine cannot be excluded as an alternative explanation for these results. Further experiments to elucidate the binding site on PLA₂ will determine whether SLD shares a binding site with substrate.

Noncovalent, hydrophobic bonding interactions have been proposed to be involved in the binding of a number of PLA₂ inhibitors. A kinetically distinct noncovalent complex, with an estimated dissociation constant of 1×10^{-3} M, was observed between the inhibitor, *p*-bromoacetophenone and cobra venom PLA₂ (*Naja naja naja*). This compound contains an aromatic group which was suggested to be involved in hydrophobic interactions with the enzyme [12]. Studies done in our laboratory with the PLA₂ inhibitor, manoalide, have suggested that the degree of hydrophobicity of the manoalide structure is an important property, conferring the potency of this inhibitor [4]. The binding constants for manoalide could not be determined due to nonlinear kinetics over a wide range of inhibitor concentrations [8]. In contrast, with SLD the binding constants could be estimated. This will allow further studies to determine the role of hydrophobic interactions between

effective inhibitors and the active site of PLA₂. It is conceivable that this property is important in allowing an inhibitor access to the active site.

Irreversible modification

The irreversible inhibitor *p*-bromophenacyl bromide (p-BPB) has been used to define and study the residues present at the active site of extracellular PLA₂s. p-BPB covalently modifies a histidine residue at the active site of PLA₂ [12, 13]. The rate of inactivation of bee venom PLA₂ occurred at a faster rate with SLD at pH 7.4 (at 41°, 100 µM) compared to p-BPB inactivation [14]. This suggests that these two inhibitors differ in their specificity and kinetic properties.

The marine natural product, manoalide, also covalently modifies PLA₂. When compared to manoalide (IC₅₀ = 0.02 µM, bee venom PLA₂), SLD had a similar potency under identical incubation conditions. Manoalide had been shown to inactivate PLA₂ through a complex mechanism. The proposed mechanism of action involves the opening of manoalide's two rings and the subsequent unmasking of two αβ-unsaturated aldehyde groups. The aldehyde groups are proposed to react with the bee venom enzyme at lysine residues near the active site [15]. These aldehydes do not appear to react synchronously or may not react in the same plane due to the flexible properties of the manoalide carbon backbone. Asymmetric binding to more than one lysine residue may also contribute to the complex inactivation kinetics, since manoalide reacts with three of eleven lysine residues on bee venom PLA₂ [15] and four of the six on cobra venom PLA₂ [5].

On the other hand, the linear inactivation kinetics obtained with SLD suggest that the interaction between SLD and bee venom PLA₂ is less complex than the manoalide reaction. Initial experiments using an analog of SLD have shown that the acetyloxy group is not necessary for inactivation of bee venom PLA₂, suggesting that the reactive groups are the aldehydes [6]. Though SLD has two aldehyde functional groups similar to those which are proposed to occur upon opening of the manoalide rings, SLD has only one αβ-unsaturated aldehyde. The aldehydes are present in an unmasked form fixed in a rigid position relative to the hydrophobic portion of the molecule, thus SLD represents a simple molecule for use in studying the structural requirements for inhibition of PLA₂. Cimino *et al.* [16] proposed the hypothesis that SLD reacts with primary amines and that the reactivity is dependent on the three-dimensional relationship of the two aldehyde groups in space. Their studies with molecules which exhibited a hot taste and contained 1,4-dialdehydes suggested that SLD reacted with primary amines under biomimetic conditions to form a pyrrole derivative, as other hot-tasting molecules did. Even though SLD was reactive with primary amines, it did not possess a hot taste. These investigators suggested that SLD was too bulky of a molecule to reach the site in the taste receptor.

The possibility that the aldehyde groups on SLD react independently and form other types of adducts with PLA₂ should be considered. Future investigations are directed toward determining the

number of binding sites for SLD on bee venom PLA₂ and their location.

Currently, there are a limited number of PLA₂ inhibitors, even though there has been a vigorous attempt to design inhibitors of PLA₂ as this enzyme has been proposed to have an important rate-limiting role in inflammation [17]. The design of affinity reagents that have an affinity for the active site of PLA₂ and are able to subsequently inactivate the enzyme is an important mechanism for the design of PLA₂ inhibitors with a degree of selectivity. Our data suggest that defining the structural requirements necessary for inhibition of PLA₂ by SLD could provide information for the development of a new class of PLA₂ inhibitors.

Acknowledgements—The authors are grateful to Dr D. J. Faulkner, Scripps Institute of Oceanography (La Jolla, CA) and Dr V. Paul, University of Guam (Mangilao, Guam) for their willingness to isolate and purify scalaradial from *Cacospongia sp.* during the course of these studies.

REFERENCES

- Burley ES, Smith B, Cutter G, Ahlem JK and Jacobs RS, Antagonism of phorbol 12-myristate 13-acetate (PMA) induced inflammation by the marine natural product, manoalide. *Pharmacologist* **24**: 117, 1982.
- Mayer AMS, Glaser KB and Jacobs RS, Regulation of eicosanoid biosynthesis *in vitro* and *in vivo* by the marine natural product manoalide: A potent inactivator of venom phospholipases. *J Pharmacol Exp Ther* **244**: 871–878, 1988.
- Cimino G, De Stefano S and Minale L, Scalaradial, a third sesterterpene with the tetracarboxylic skeleton of scalarin, from the sponge *Cacospongia mollior*. *Experientia* **30**: 846–847, 1974.
- Glaser KB, S. de Carvalho M, Jacobs RS, Kernan MR and Faulkner DJ, Manoalide: Structure–activity studies and definition of the pharmacophore for phospholipase A₂ inactivation. *Mol Pharmacol* **36**: 782–788, 1989.
- Lombardo D and Dennis EA, Cobra venom phospholipase A₂ inhibition by manoalide. A novel type of phospholipase inhibitor. *J Biol Chem* **260**: 7234–7240, 1985.
- S. de Carvalho M and Jacobs RS, Inhibition of eicosanoid release by scalaradial, a phospholipase A₂ inhibitor. *Pharmacologist* **32**: 168, 1990.
- Bradford M, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**: 248–254, 1976.
- Glaser KB and Jacobs RS, Molecular pharmacology of manoalide. Inactivation of bee venom phospholipase A₂. *Biochem Pharmacol* **35**: 449–453, 1986.
- Kitz R and Wilson IB, Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. *J Biol Chem* **237**: 3245–3249, 1962.
- Glaser KB and Jacobs RS, Inactivation of bee venom phospholipase A₂ by manoalide. A model based on the reactivity of manoalide with amino acids and peptide sequences. *Biochem Pharmacol* **36**: 2079–2086, 1987.
- Segal IH, *Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems*. John Wiley, New York, 1975.
- Fedarko Roberts M, Deems RA, Mincey TC and Dennis EA, Chemical modification of the histidine residue in phospholipase A₂ (*Naja naja naja*). *J Biol Chem* **252**: 2405–2411, 1977.
- Volwerk JJ, Pieterse WA and de Haas GH, Histidine

- at the active site of phospholipase A_2 . *Biochemistry* **13**: 1446–1454, 1974.
14. Glaser KB, Molecular pharmacology of the marine natural product manoalide: Irreversible inactivation of bee venom phospholipase A_2 . *Ph.D. Dissertation*, pp. 48–49. University of California, Santa Barbara, CA, 1987.
 15. Glaser KB, Vedvick TS and Jacobs RS, Inactivation of phospholipase A_2 by manoalide: Localization of the manoalide binding site on bee venom phospholipase A_2 . *Biochem Pharmacol* **37**: 3639–3646, 1988.
 16. Cimino G, Sodano G and Spinella A, Correlation of the reactivity of 1,4-dialdehydes with methylamine in biomimetic conditions to their hot taste. *Tetrahedron* **43**: 5401–5410, 1987.
 17. Irvine RF, How is the level of free arachidonic acid controlled in mammalian cells? *Biochem J* **204**: 3–16, 1982.